Found to have 78 percent efficacy after two doses spread
over four weeks, the vaccine “is extremely suitable for low- and middle-income
countries due to easy storage requirements,” the UN body said in a statement.
Covaxin is the first vaccine completely developed and
manufactured in India to receive WHO approval.
Based on inactivated coronavirus antigens, it becomes the
eighth vaccine against Covid-19 on the WHO’s list, including others from
Pfizer/BioNTech, Moderna, AstraZeneca, Johnson & Johnson, Sinopharm, and
Sinovac.
WHO emergency approval, which includes an assessment of
clinical trial data, can speed up international recognition of vaccines.
It also allows their use by fellow UN agencies and the
global Covax initiative, set up to immunise people in the world’s
least-well-off countries.
0 comments:
Post a Comment